Understand the source comparison
Follistatin-344 Safe Long Term Use: Comparison of Study Durations and Findings
Rodent (C57BL/6 mice) 12–16 weeks 0.5–2 mg/kg biweekly 15–20% lean mass increase, no hepatotoxicity or nephrotoxicity markers Short observation window, species extrapolation uncertain Demonstrates acute safety but insufficient for long-term human conclusions P
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Rodent (C57BL/6 mice)
- 12–16 weeks
- 0.5–2 mg/kg biweekly
- 15–20% lean mass increase, no hepatotoxicity or nephrotoxicity markers
- Short observation window, species extrapolation uncertain
- Demonstrates acute safety but insufficient for long-term human conclusions
- Primate (rhesus macaque)
- 24 weeks
- 1–3 mg/kg biweekly
- 12% lean mass increase, no elevated liver enzymes or inflammatory markers
- Only 6-month follow-up, small sample size (n=8 per group)
- Longest controlled mammalian data available. Still far short of multi-year human exposure
- Human gene therapy (muscular dystrophy patients)
- 12–18 months
- AAV-mediated follistatin overexpression
- No serious adverse events attributed to follistatin at follow-up
- Disease population, not performance context; gene therapy delivery differs from peptide injection
- Provides human exposure data but baseline pathology limits generalisability to healthy individuals
- Healthy human cohort
- No data
- N/A
- No published trials exist
- This is the critical gap. We lack longitudinal safety data in non-diseased populations